走进利拉鲁肽 更多 >>
继日本中央社会保险医疗委员会批准了Victoza®（利拉鲁肽）的定价之后，诺和诺德制药公司计划将尽快在当地市场推出这种产品。诺和诺德表示，Victoza®是首个在日本获准上市的GLP-1类药物，既可以单独用药，也可以作为辅助药物与磺脲类降糖药(SU)联用。
Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite
本研究采用GLP-1阻滞剂进行研究，结果发现该物质可以减弱瘦素对于食欲的抑制。证实内源性的GLP-1可以影响瘦素（leptin）对于摄食中枢的调节。
Leptin and glucagon-like peptide-1 (GLP-1) were proved to act in concert to control the activity of feeding centres. Since leptin receptor was identified in the gut endocrine L cells and neurons producing GLP-1, we have checked whether GLP-1 mediates the effects of leptin on feeding and drinking behaviour.
To this aim, an intraperitoneal or intracerebroventricular injection of exendin (9 - 39), a GLP-1 antagonist, (50 or 10 µg per rat, respectively) followed by leptin (100 or 5 µg per rat, respectively) was made and 24-hour food intake and body weight changes were measured. Previous injection of exendin (9 - 39) completely abolished the suppressory effect of peripheral leptin on food intake and body weight gain. Moreover, exendin (9 - 39) significantly attenuated the effect of intracerebroventricular leptin on food but not water consumption.
It is concluded that intact GLP-1 signalling is necessary to mediate the effect of leptin on food intake in the rat. Conversely, leptin seems to affect the thirst center function independently of GLP-1. Also, these findings produce further evidence for close interactions between long- and short-term factors regulating the activity of feeding centres.
编辑: helen
以下网友留言只代表网友个人观点，不代表网站观点
